Novartis agreed to a potential $900 million deal to secure exclusive global rights to a preclinical radioligand therapy asset from Boomray Pharmaceuticals, the companies said. The move is positioned as Novartis works to defend and expand its radioligand franchise as competition grows around Lutathera. The deal adds a new preclinical radioligand therapy program to Novartis’ pipeline while staving off competitive pressure in radioligand therapy—an area where manufacturing capacity and isotope supply are increasingly central to execution. Boomray currently lists BRP-0X0 (Ga 68, Lu 177) as a preclinical-stage diagnostic radioligand program for solid tumors; details of the specific licensed therapy asset were not disclosed in the summary provided. For the sector, the agreement signals continued big-pharma willingness to pay for radioligand pipeline options at the preclinical stage, with deal terms reflecting modality risk and the strategic value of radiopharma manufacturing scale.